🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in Nature Communications our multi-center analysis led by🌟 João Alessi, MD. #biomarkers can help⬆️outcomes. OncoAlert #LCSM

New #JITC article: Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study jitc.bmj.com/content/11/7/e… @ArielleElkrief João Alessi, MD Xinan Wang Charlie Rudin Mark Awad

Very nice preprint. The authors predict "personalized" accuracy (unexplained variance) of polygenic scores, using regression on age, sex, ancestry, and socioeconomic factors. The predicted variance is used to construct calibrated confidence intervals. medrxiv.org/content/10.110…

Thanks IASLC #WCLC23 for recognizing our work on smoking cessation and OS among pts w/ NSCLC. This is my first WCLC and I am extremely honored to receive the Tobacco Control & Smoking Cessation Early Career Award! David Christiani Harvard Chan ERC Harvard T.H. Chan School of Public Health MGH Division of Pulmonary & Critical Care Medicine

Fantastic talk by 🌟Biagio Ricciuti, MD PhD showing Pembro monotherapy continues to demonstrate a meaningful long-term survival benefit in pts w/ advanced NSCLC and a PD-L1 ≥90%. NSCLCs with very high PD-L1 may have a more favorable genomic and immunophenotypic profile. #WCLC23 IASLC

The #WCLC23 Tobacco Control & Smoking Cessation Education Award Winners have been announced. Congratulations! #LCSM

I'm delighted to release the first half of my new open-access online textbook in human population genetics: web.stanford.edu/group/pritchar…

Glad to join BMC Cancer!

I'm writing a molecular perspective on heritability, behavior, (and eventually) race/ancestry, group differences. The idea is to start with what we've learned from genetic data and then work backwards to what we used to know from classical studies. gusevlab.org/projects/hsq/

New #JITC short report: Multi-institutional analysis of aneuploidy & outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer bit.ly/3SmC1wI João Alessi, MD Xinan Wang @ArielleElkrief Emily Lebow, MD Trisha Santos, MD, MS Adam J. Schoenfeld Mark Awad #SITC23

🚨Out in Journal of Clinical Oncology our work dissecting the genomic & immunophenotypic correlates of acquired resistance (AR) to PD-(L)1 blockade in #NSCLC. OncoAlert #LCSM Dana-Farber News ASCO IASLC Link: shorturl.at/qyIJ4 1/9

In a new study published in Journal of Clinical Oncology, Mark Awad, @BiagioRicciutiMD, and Giuseppe Lamberti Dana-Farber have uncovered mechanisms of resistance to immunotherapy in metastatic non-small-cell lung cancer. Research Summary ▶️ ms.spr.ly/6013ioykh

In Annals of Oncology, Biagio Ricciuti, MD PhD & coll. review challenges & opportunities for TMB & immunotherapy: 🔹Technical limitations 🔹Spatial & temporal heterogeneity 🔹Co-occuring genomic and non-genomic factors 🔹Strategies to improve predictivity annalsofoncology.org/article/S0923-… 2/2

Take a look at our comprehensive review on tumor mutational burden (TMB) and its application in clinical practice, led by Biagio Ricciuti, MD PhD Xinan Wang and just published in Annals of Oncology ESMO - Eur. Oncology

Thanks Annals of Oncology for featuring our review on how to optimize the use of #TMB for predicting #ICI efficacy on this month’s cover. ESMO - Eur. Oncology Here we reviewed challenges & opportunities for TMB & immunotherapy focusing on: -Technical limitations 🔬 -Spatial & temporal

Out in Nature Communications our collaborative effort showing how adaptive mechanisms & increased GTP loading confer resistance to #KRAS G12C OFF 💊. Selective inhibitor RMC-4998 targeting GTP-bound (ON) KRAS can overcome resistance. W/ AmbrogioLab OncoAlert nature.com/articles/s4146…

Join us for the 2024 Harvard PQG conference on "AI for Genomics and Health" in Boston on Oct 17-18, 2024. A fantastic lineup of speakers. See three topics below. Early bird registration and abstracts due on 9/15. Stellar abstract awards. Pls RT hsph.harvard.edu/pqg-conference/

Join us with Aoxing Liu next Tuesday at HSPH, and we got a fantastic lineup of speakers! Stay tuned! Harvard T.H. Chan School of Public Health Harvard Biostatistics Dana-Farber Data Science Harvard Epidemiology

Just in time! Come join us with Saori Sakaue on 11/19 for her recent work revealing genetic regulatory mechanisms through eQTL causal variants! Harvard Biostatistics Harvard Epidemiology

Excited to kick off with the amazing Dr. Kun-Hsing Yu Kun-Hsing Yu! Come join us tomorrow Harvard Biostatistics Harvard Epidemiology